主页 > 医学讨论 >
【文摘发布】omega-3 脂肪酸（鱼油）对于患有Ig
Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC; North American IgA Nephropathy Study Group.
St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA. spnsg@chw.edu
Previous studies that have evaluated fish oil preparations in patients with IgA nephropathy (IgAN) have produced a wide range of conclusions. Proposed explanations for these discordant results have not provided a unifying hypothesis.
Results from two clinical trials were analyzed to examine whether there is a dosage-dependent effect of Omacor, a purified preparation of omega-3 fatty acids, in patients with IgAN. Whether changes in the level of proteinuria and plasma phospholipid fatty acid profiles were dependent on the dose of Omacor factored by body size was determined. In a post hoc analysis of the first trial results, correlations were found between (1) phospholipid eicosapentaenoic acid (EPA)/arachidonic acid (AA) and docosahexaenoic acid (DHA)/AA ratios and the dosage of Omacor, expressed as milligrams per kilogram of body weight (r = 0.78, P < 0.001 for EPA/AA; r = 0.86, P < 0.001 for DHA/AA), (2) phospholipid EPA/AA and DHA/AA levels and percentage change in urine protein/creatinine ratio after 21 to 24 mo of therapy (r = -0.50, P = 0.02 for EPA/AA; r = -0.52, P = 0.01 for DHA/AA), and (3) dosage of Omacor per kilogram of body weight and change in proteinuria after 21 to 24 mo (r = -0.50, P = 0.02). A similar relationship was observed between urine protein/creatinine ratio and dosage of Omacor per kilogram of body weight in trial 2 (r = -0.38, P < 0.001).
It is concluded from these data that the effect of Omacor on proteinuria in patients with IgAN is dosage dependent and is associated with a dosage-dependent effect of Omacor on plasma phospholipid EPA and DHA levels. 已认领！ Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.Hogg RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC; North American IgA Nephropathy Study Group. omega-3脂肪酸对于IgA肾病的儿童和成人的疗效呈剂量依赖。RJ, Fitzgibbons L, Atkins C, Nardelli N, Bay RC;北美IgA肾病研究小组。
St. Joseph's Hospital and Medical Center, Phoenix, AZ 85013, USA. spnsg@chw.edu
Previous studies that have evaluated fish oil preparations in patients with IgA nephropathy (IgAN) have produced a wide range of conclusions. Proposed explanations for these discordant results have not provided a unifying hypothesis. 以前关于鱼油对IgA肾病（IgAN）者的疗效有很多结论。对于不同的结论却还没有统一的解释。
Results from two clinical trials were analyzed to examine whether there is a dosage-dependent effect of Omacor, a purified preparation of omega-3 fatty acids, in patients with IgAN. Whether changes in the level of proteinuria and plasma phospholipid fatty acid profiles were dependent on the dose of Omacor factored by body size was determined.
通过两个临床试验的结果分析检测Omacor ，一种纯化的omega-3脂肪酸，其对IgA肾病者疗效是否存在剂量依赖。蛋白尿和血浆磷酸脂肪酸的改变依赖于体内Omacor的量已得到肯定。
In a post hoc analysis of the first trial results, correlations were found between (1) phospholipid eicosapentaenoic acid (EPA)/arachidonic acid (AA) and docosahexaenoic acid (DHA)/AA ratios and the dosage of Omacor, expressed as milligrams per kilogram of body weight (r = 0.78, P < 0.001 for EPA/AA; r = 0.86, P < 0.001 for DHA/AA),
因此分析第一个试验结果，（1）磷酸二十碳五烯酸（EPA）/花生四烯酸（AA）及二十二碳六烯酸（DHA）/AA的比值和Omacor的剂量存在相关性，以毫克/每公斤体重表示（r = 0.78, P < 0.001 for EPA/AA; r = 0.86, P < 0.001 for DHA/AA）
(2) phospholipid EPA/AA and DHA/AA levels and percentage change in urine protein/creatinine ratio after 21 to 24 mo of therapy (r = -0.50, P = 0.02 for EPA/AA; r = -0.52, P = 0.01 for DHA/AA), and (3) dosage of Omacor per kilogram of body weight and change in proteinuria after 21 to 24 mo (r = -0.50, P = 0.02). A similar relationship was observed between urine protein/creatinine ratio and dosage of Omacor per kilogram of body weight in trial 2 (r = -0.38, P < 0.001).（2）磷酸EPA/AA和DHA/AA以及尿蛋白/肌酐比值的百分比在治疗组下降了21到24摩尔（r = -0.50, P = 0.02 for EPA/AA; r = -0.52, P = 0.01 for DHA/AA），（3）每公斤体重Omacor的剂量和蛋白尿下降了21到24摩尔（r = -0.50, P = 0.02）。在试验2中，尿蛋白/肌酐比值和每公斤体重Omacor的剂量也存在相似关系(r = -0.38, P < 0.001)。
It is concluded from these data that the effect of Omacor on proteinuria in patients with IgAN is dosage dependent and is associated with a dosage-dependent effect of Omacor on plasma phospholipid EPA and DHA levels.由此推断，Omacor对IgA肾病病人蛋白尿的药效呈剂量依赖并且与Omacor对血浆磷酸EPA和DHA水平的剂量依赖有关。 整理如下：
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-14 17:16
医学,生命科学网